BioAlliance Pharma licenses European marketing rights of two drugs to Therabel
Paris – French BioAlliance Pharma SA has licenced the European marketing rights for its drugs Loramyc and Setofilm exclusively to the newly established entity, Therabel Hôpital Pharma, part of the Therabel Group. BioAlliance will receive up to EUR48.5 million (Eur6.5 million upfront) from Therabel. In addition, EUR3 million will be linked to Loramyc reimbursement in three EU countries, with the remainder of the EUR33 million linked to sales performance for the two licensed products.The agreement includes significant royalties on sales of the two approved products in EU. It also includes an equity investment from Therabel as a strategic partner in BioAlliance of EUR3 million, subject to shareholders’ approval. Loramyc is an antifungal treatment for the treatment of oropharyngeal candidiasis in immunocompromised patients. Setofilm is an anti-emetic drug for prevention and treatment of chemotherapy, radiotherapy and post operative-induced nausea and vomiting in adults and children.